ClinicalTrials.gg
CompletedNCT01140347REACHUpdated Dec 28, 2015Results posted

A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib

A Phase 3 interventional study of Placebo and Ramucirumab DP (IMC-1121B) in Hepatocellular Carcinoma, sponsored by Eli Lilly and Company. Completed at 146 sites in 27 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-12-28.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
565
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies in Carcinoma, Hepatocellular by Eli Lilly and Company — none open to participants now, none under way, none of them phase 3. Carcinoma, Hepatocellular · Eli Lilly and Company.

Enrollment
Largest of 13
565 · median 47
Started
2010
the only one that year
Phase 3
2 of 13
none open now
Registered
4th of 13
by date

Among the 13 studies in Carcinoma, Hepatocellular by Eli Lilly and Company, this one has the largest enrollment, is the only one that started in 2010, is one of 2 in phase 3, and was the 4th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,062 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

None of the 13 studies in Carcinoma, Hepatocellular by Eli Lilly and Company is open now. The open studies under Carcinoma, Hepatocellular, anywhere →

Who these studies take

Of the 737 Carcinoma, Hepatocellular studies recruiting now, 382 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Carcinoma, Hepatocellular by Eli Lilly and Company as a file.
02

Study summary

This is a Phase 3 multicenter, randomized study evaluating the safety and efficacy of ramucirumab DP plus BSC as a double-blind, placebo-controlled (placebo plus BSC) comparison.

Approximately 544 participants, at least 18 years of age, with Child-Pugh score \< 7 and diagnosed with hepatocellular carcinoma will be randomized. Participants must have received sorafenib as first-line systemic treatment for hepatocellular carcinoma (HCC), and must have discontinued sorafenib prior to entering the study.

Hypothesis: This sample size will allow differentiation of the expected increase in median overall survival (OS), from 8 months in the placebo arm to 10.67 months in the ramucirumab arm.

Upon registration and completion of screening procedures, eligible participants with HCC who have disease progression during or following first-line therapy with sorafenib, or were intolerant to this agent, will be randomized to receive either ramucirumab DP or placebo.

The treatment regimen will be continued until radiographic or symptomatic progression, the development of unacceptable toxicity, noncompliance or withdrawal of consent by the participant, or investigator decision.

03

Conditions studied

  • Hepatocellular Carcinoma

Keywords

  • Hepatocellular carcinoma (HCC)
  • recombinant human immunoglobulin G
  • subclass 1 (IgG1) monoclonal antibody (MAb)
  • Hepatocellular Carcinoma (HCC) following First-Line Therapy With Sorafenib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ECOG) Performance Status (PS) of 0 or 1
  • score of \<7 (Child-Pugh Class A only)
  • Barcelona Clinic Liver Cancer (BCLC) Stage C or BCLC stage B not amenable to locoregional therapy or to locoregional therapy
  • Diagnosis of HCC (excluding fibrolamellar carcinoma) in the absence of histologic or cytologic confirmation
  • There are either clinical, laboratory, or radiographic findings consistent with a diagnosis of liver cirrhosis
  • Has a liver mass measuring at least 2 centimeters (cm) with characteristic vascularization seen on either triphasic computed tomography (CT) scan or magnetic resonance imaging (MRI) with gadolinium
  • At least 1 measurable or evaluable lesion that is viable [that is (i.e.), is vascularized], and has not been previously treated with locoregional therapy. A lesion that has been previously treated will qualify as a measurable or evaluable lesion if there was demonstrable progression following locoregional therapy
  • Previously treated with sorafenib and has discontinued sorafenib treatment at least 14 days prior to randomization. Participants may have experienced:

    • Radiographically documented disease progression during sorafenib therapy or after discontinuation of sorafenib therapy, or
    • Discontinuation of sorafenib due to an adverse drug reaction, despite dose reduction by 1 level and BSC
  • The participant has received sorafenib as the only systemic therapeutic intervention. Any hepatic locoregional therapy that has been administered prior to sorafenib is allowed, but not following sorafenib. Radiation to sites [for example (e.g.), bone] following sorafenib therapy is permitted.
  • Resolution of toxicity of any anti-cancer therapy to Grade ≤1 by the National Cancer Institute volume 4.0 (NCI-CTCAE v. 4.0).

Adequate Organ Function defined as:

  • Total \<3.0 milligrams/deciliter (mg/dL) [51.3 micromole/liter (µmol/L)], (AST) and alanine aminotransferase (ALT) ≤5 × (ULN)
  • Serum creatinine ≤1.2 × ULN or calculated >50 milliliters/minute (mL/min)
  • (ANC) ≥1.0 × 10\^3/microliter (μL) (1.0 × 10\^9/liter (L)]), ≥9 grams/deciliter (g/dL) [5.58 millimoles/liter (mmol/L)], and ≥75 × 10\^3/µL (75 × 10\^9/L)
  • (INR) ≤1.5 and partial thromboplastin time (PTT) ≤5 seconds above ULN. Participants receiving prophylactic low-dose anticoagulant therapy are eligible provided that INR ≤1.5 and PTT ≤5 seconds above the ULN
  • The participant's urinary protein is ≤1+ on dipstick or routine urinalysis. If urine dipstick or routine analysis indicates ≥2+ proteinuria, then a 24-hour urine must be collected and must demonstrate \<1000 milligrams (mg) of protein in 24 hours to allow participation in the study

Exclusion criteria

Exclusion criteria:

  • Major surgery within 28 days prior to randomization, or central venous access device placement within 7 days prior to randomization
  • Hepatic locoregional therapy within 28 days prior to randomization
  • Radiation to any nonhepatic (e.g., bone) site within 14 days prior to randomization
  • Sorafenib within 14 days prior to randomization
  • Received any therapy or non-approved drug within 28 days prior to randomization
  • Received any previous systemic therapy with vascular endothelial growth factor (VEGF) inhibitors or vascular endothelial growth factor receptor (VEGFR) inhibitors (including investigational agents) other than sorafenib for treatment of HCC
  • Fibrolamellar carcinoma
  • Received any transfusion, blood component preparation, erythropoietin, albumin preparation, or granulocyte colony-stimulating factors (G-CSF) within 14 days prior to randomization
  • Therapeutic anticoagulation with warfarin, low-molecular-weight heparin, or similar agents. Participants receiving prophylactic, low-dose anticoagulation therapy are eligible provided that the coagulation parameters defined in the inclusion criteria ( ≤1.5 and PTT ≤5 seconds above the ) are met
  • Receiving ongoing therapy with nonsteroidal anti-inflammatory agents (NSAIDs, e.g., indomethacin, ibuprofen, naproxen, nimesulide, celecoxib, etoricoxib, or similar agents) or other antiplatelet agents (e.g., clopidogrel, ticlopidine, prasugrel, dipyridamole, picotamide, indobufen, anagrelide, triflusal). Aspirin (ASA) at doses up to 100 milligrams/day (mg/day) is permitted
  • Symptomatic congestive heart failure, unstable angina pectoris, or symptomatic or poorly controlled cardiac arrhythmia
  • Any arterial thrombotic event, including myocardial infarction, unstable angina, cerebrovascular accident, or , within 6 months prior to randomization
  • Uncontrolled arterial hypertension systolic ≥150 / diastolic ≥90 millimeters of mercury (mm Hg) despite standard medical management
  • Grade 3-4 gastrointestinal bleeding or any variceal bleeding episode in the 3 months prior to randomization requiring transfusion, endoscopic or operative intervention (participants with any bleeding episode considered life-threatening during the 3 months prior to randomization are excluded, regardless of transfusion or intervention status)
  • Esophageal or gastric varices that require immediate intervention (e.g., banding, sclerotherapy) or represent a high bleeding risk. Participants with evidence of portal hypertension (including splenomegaly) or any prior history of variceal bleeding must have had endoscopic evaluation within the 3 months immediately prior to randomization. Participants with evidence of portal hypertension are eligible for study participation if endoscopic evaluation does not indicate esophageal or gastric varices that require immediate intervention or represent a high bleeding risk; however, these eligible participants must receive supportive therapy (e.g., beta blocker therapy) according to institutional standards and clinical guidelines during study participation
  • Central nervous system (CNS) or carcinomatous meningitis
  • History of or current hepatic encephalopathy or current ascites
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
565 participants (actual)

Study arms

  • Experimental
    Ramucirumab DP and BSC

    Biological: Ramucirumab DP (IMC-1121B) · Other: BSC

  • Placebo comparator
    Placebo and BSC

    Biological: Placebo · Other: BSC

Interventions

  • BiologicalPlacebo

    8 mg/kg IV every 2 weeks

  • 8 milligrams/kilogram (mg/kg) intravenous (IV) every 2 weeks

    Also known as: IMC-1121B, LY3009806

  • OtherBSC

    Palliative and supportive care for disease-related symptoms and toxicity associated with treatment as deemed medically necessary and appropriate in the opinion of the investigator.

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS was defined as the time from the date of randomization to the date of death from any cause. Participants who were alive at the end of the follow-up period or were lost to follow-up were censored on the last date the participant was known to be alive.

    Time frame: Randomization to death from any cause (up to 37 months)

Secondary outcomes

  1. Progression-Free Survival (PFS)

    PFS was defined as time from date of randomization until date of objectively determined progressive disease (PD) as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 or death from any cause. PD was defined as ≥20% increase in sum of diameters (SOD) of target lesions, taking as reference smallest sum on study (including baseline sum if it was smallest). Sum must show a ≥5 millimeter (mm) increase. Appearance of ≥1 new lesions and unequivocal progression of existing non-target lesions were considered progression. In primary analysis, participants alive and without PD were censored at day of last adequate tumor assessment; progression or deaths without progression occurring immediately after ≥2 missed tumor assessments, were censored at day of the last adequate tumor assessment prior to missing assessments; participants who began new anticancer therapy were censored at day of the last adequate tumor assessment prior to start of new anticancer therapy.

    Time frame: Randomization to PD (up to 36 months)

  2. Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)]

    ORR was defined, using RECIST v1.1 criteria, as the percentage of participants who achieved a best overall response of CR or PR. CR was defined as the disappearance of all lesions and any intratumor arterial enhancement in target lesions, the normalization of the tumor marker level and all lymph nodes short axis reduced to \<10 mm. PR was defined as ≥30% decrease in the SOD of target lesions, including the short axes of any target lymph nodes, taking as reference the baseline SOD of target lesions, no new lesions and stable nontarget lesions. Percentage of participants was calculated as: (number of participants with CR or PR / number of participants randomized) \* 100.

    Time frame: Baseline to the date of first evidence of confirmed CR or PR (up to 37 months)

  3. Time to Radiographic Progression (TTP)

    TTP was defined as the time from randomization to the first radiographically documented PD. PD was defined, using RECIST v1.1 criteria, as ≥20% increase in SOD of target lesions, taking as reference smallest sum on study (including baseline sum if it was the smallest). Sum must show an absolute increase of ≥5 mm. Appearance of ≥1 new lesions and unequivocal progression of existing non-target lesions were considered progression. Participants without PD were censored at the day of the last adequate tumor assessment. Progression occurred immediately after ≥2 missed tumor assessments and were censored at the day of the last adequate tumor assessment prior to the missing assessments. Participants who began new anticancer therapy were censored at the day of their last adequate tumor assessment prior to start of new anticancer therapy.

    Time frame: Randomization to PD (up to 36 months)

  4. Change From Baseline in the Functional Assessment of Cancer Therapy (FACT) Hepatobiliary Symptom Index-8 (FHSI-8)

    The FHSI-8 is a self-administered 8-item questionnaire that measures a participant's symptoms in the domains of jaundice, stomach pain/discomfort weight loss, and fatigue. Participants rated each item on a 5-point scale from 0 (not at all) to 4 (very much). Item scores were calculated as outlined in the FACIT manual. FHSI-8 total score was the sum of each item's score with a total score ranging from 0 (highly symptomatic) to 32 (asymptomatic).

    Time frame: Baseline, Prior to infusion on Day 1 of Cycle 4, Cycle 10, and Cycle 16 (14-day cycles), and end of treatment (up to 34 months)

  5. Change From Baseline in European Quality of Life Questionnaire-5 Dimensions (EQ-5D) Health State Score

    The EQ-5D is a self-reported, 5-dimension (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) questionnaire related to the participant's current health state. Each question was scored using a 3 level scale (no problems, some problems, or extreme problems). EQ-5D health state was defined by combining responses from each of the 5 dimensions into a weighted health-state index score according to the United Kingdom (UK) population based algorithm where 0 = death and 1 = perfect health.

    Time frame: Baseline, Prior to infusion on Day 1 of Cycle 4, Cycle 10, and Cycle 16 (14-day cycles), end of treatment (up to 34 months)

  6. Number of Participants With Adverse Events (AEs) and the Number of Participants Who Died

    The number of participants with serious AEs (SAEs), other non-serious AEs and participants who died. A summary of SAEs and other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.

    Time frame: Baseline to study completion (up to 37 months)

  7. Maximum Concentration (Cmax) of Ramucirumab, Cycle 1

    Time frame: 1 hour following the completion of Cycle 1 (14-day cycle) infusion

  8. Cmax of Ramucirumab, Cycle 4

    Time frame: 1 hour following completion of Cycle 4 (14-day cycles) infusion

  9. Cmax of Ramucirumab, Cycle 7

    Time frame: 1 hour following completion of Cycle 7 (14-day cycles) infusion

  10. Number of Participants With Treatment Emergent Positive Anti-Ramucirumab Response [Serum Anti-Ramucirumab Antibody Assessment (Immunogenicity)]

    Participants were considered positive for anti-ramucirumab antibodies \[anti-drug antibodies (ADA)\] if the post-treatment sample had an increase of at least 4-fold in titer from the pretreatment values. If the pretreatment value was not detected or was not present, a 1:20 post-treatment titer was required to indicate treatment emergence of ADA.

    Time frame: Prior to treatment and 1 hour post end of infusion for Cycles 1, 4 and 7 (14-day cycles)

07

Results

Posted Mar 26, 2015

Participant flow

Participant flow — Overall Study
MilestoneRamucirumab (IMC-1121B) + BSCPlacebo + BSC
Started283282
Received at least 1 dose of study drug277276
Completed265268
Not completed1814
Withdrew: Lost to follow-up56
Withdrew: Withdrawal by subject138

Outcome measures

PrimaryOverall Survival (OS)

OS was defined as the time from the date of randomization to the date of death from any cause. Participants who were alive at the end of the follow-up period or were lost to follow-up were censored on the last date the participant was known to be alive.

Time frame:
Randomization to death from any cause (up to 37 months)
Reported as:
Median · months
Overall Survival (OS)
monthsRamucirumab (IMC-1121B) + BSCPlacebo + BSC
Overall Survival (OS)9.17 (8.05 to 10.64)7.62 (6.01 to 9.33)
Statistical analysis
  • Ramucirumab (IMC-1121B) + BSC vs Placebo + BSC · Log Rank · p = 0.1391 · Hazard ratio (hr): 0.866 · 95% CI 0.717 to 1.046HR with 95% confidence interval (CI) was estimated using a stratified Cox proportional hazards regression model using the Interactive Web Response System (IWRS) stratification factors (geographical regions and etiology of liver disease).
SecondaryProgression-Free Survival (PFS)

PFS was defined as time from date of randomization until date of objectively determined progressive disease (PD) as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 or death from any cause. PD was defined as ≥20% increase in sum of diameters (SOD) of target lesions, taking as reference smallest sum on study (including baseline sum if it was smallest). Sum must show a ≥5 millimeter (mm) increase. Appearance of ≥1 new lesions and unequivocal progression of existing non-target lesions were considered progression. In primary analysis, participants alive and without PD were censored at day of last adequate tumor assessment; progression or deaths without progression occurring immediately after ≥2 missed tumor assessments, were censored at day of the last adequate tumor assessment prior to missing assessments; participants who began new anticancer therapy were censored at day of the last adequate tumor assessment prior to start of new anticancer therapy.

Time frame:
Randomization to PD (up to 36 months)
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsRamucirumab (IMC-1121B) + BSCPlacebo + BSC
Progression-Free Survival (PFS)2.79 (2.69 to 3.94)2.10 (1.58 to 2.69)
Statistical analysis
  • Ramucirumab (IMC-1121B) + BSC vs Placebo + BSC · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.625 · 95% CI 0.522 to 0.750HR with 95% CI was estimated using a stratified Cox proportional hazards regression model using the IWRS stratification factors (geographical regions and etiology of liver disease).
SecondaryPercentage of Participants With Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)]

ORR was defined, using RECIST v1.1 criteria, as the percentage of participants who achieved a best overall response of CR or PR. CR was defined as the disappearance of all lesions and any intratumor arterial enhancement in target lesions, the normalization of the tumor marker level and all lymph nodes short axis reduced to \<10 mm. PR was defined as ≥30% decrease in the SOD of target lesions, including the short axes of any target lymph nodes, taking as reference the baseline SOD of target lesions, no new lesions and stable nontarget lesions. Percentage of participants was calculated as: (number of participants with CR or PR / number of participants randomized) \* 100.

Time frame:
Baseline to the date of first evidence of confirmed CR or PR (up to 37 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)]
percentage of participantsRamucirumab (IMC-1121B) + BSCPlacebo + BSC
Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)]7.1 (4.6 to 10.7)0.7 (0.2 to 2.5)
Statistical analysis
  • Ramucirumab (IMC-1121B) + BSC vs Placebo + BSC · Cochran-Mantel-Haenszel · p = <0.0001Cochran-Mantel-Haenszel (CMH) adjusted for geographic region and etiology liver disease
SecondaryTime to Radiographic Progression (TTP)

TTP was defined as the time from randomization to the first radiographically documented PD. PD was defined, using RECIST v1.1 criteria, as ≥20% increase in SOD of target lesions, taking as reference smallest sum on study (including baseline sum if it was the smallest). Sum must show an absolute increase of ≥5 mm. Appearance of ≥1 new lesions and unequivocal progression of existing non-target lesions were considered progression. Participants without PD were censored at the day of the last adequate tumor assessment. Progression occurred immediately after ≥2 missed tumor assessments and were censored at the day of the last adequate tumor assessment prior to the missing assessments. Participants who began new anticancer therapy were censored at the day of their last adequate tumor assessment prior to start of new anticancer therapy.

Time frame:
Randomization to PD (up to 36 months)
Reported as:
Median · months
Time to Radiographic Progression (TTP)
monthsRamucirumab (IMC-1121B) + BSCPlacebo + BSC
Time to Radiographic Progression (TTP)3.48 (2.76 to 4.47)2.63 (1.58 to 2.76)
Statistical analysis
  • Ramucirumab (IMC-1121B) + BSC vs Placebo + BSC · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.593 · 95% CI 0.487 to 0.722HR with 95% CI was estimated using a stratified Cox proportional hazards regression model using the IWRS stratification factors (geographical regions and etiology of liver disease).
SecondaryChange From Baseline in the Functional Assessment of Cancer Therapy (FACT) Hepatobiliary Symptom Index-8 (FHSI-8)

The FHSI-8 is a self-administered 8-item questionnaire that measures a participant's symptoms in the domains of jaundice, stomach pain/discomfort weight loss, and fatigue. Participants rated each item on a 5-point scale from 0 (not at all) to 4 (very much). Item scores were calculated as outlined in the FACIT manual. FHSI-8 total score was the sum of each item's score with a total score ranging from 0 (highly symptomatic) to 32 (asymptomatic).

Time frame:
Baseline, Prior to infusion on Day 1 of Cycle 4, Cycle 10, and Cycle 16 (14-day cycles), and end of treatment (up to 34 months)
Reported as:
Mean · units on a scale
Change From Baseline in the Functional Assessment of Cancer Therapy (FACT) Hepatobiliary Symptom Index-8 (FHSI-8)
units on a scaleRamucirumab (IMC-1121B) + BSCPlacebo + BSC
Cycle 4 (n=166, 147)-1.26 ± 3.164-0.81 ± 4.623
Cycle 10 (n=70, 45)-1.28 ± 3.989-0.01 ± 4.378
Cycle 16 (n=47, 24)-0.97 ± 4.0950.75 ± 3.768
End of Treatment (n=169, 199)-2.44 ± 5.561-2.86 ± 5.618
SecondaryChange From Baseline in European Quality of Life Questionnaire-5 Dimensions (EQ-5D) Health State Score

The EQ-5D is a self-reported, 5-dimension (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) questionnaire related to the participant's current health state. Each question was scored using a 3 level scale (no problems, some problems, or extreme problems). EQ-5D health state was defined by combining responses from each of the 5 dimensions into a weighted health-state index score according to the United Kingdom (UK) population based algorithm where 0 = death and 1 = perfect health.

Time frame:
Baseline, Prior to infusion on Day 1 of Cycle 4, Cycle 10, and Cycle 16 (14-day cycles), end of treatment (up to 34 months)
Reported as:
Mean · units on a scale
Change From Baseline in European Quality of Life Questionnaire-5 Dimensions (EQ-5D) Health State Score
units on a scaleRamucirumab (IMC-1121B) + BSCPlacebo + BSC
Cycle 4 (n=166, 145)-0.038 ± 0.189-0.046 ± 0.245
Cycle 10 (n=71, 45)-0.054 ± 0.2120.003 ± 0.148
Cycle 16 (n=47, 25)-0.062 ± 0.214-0.012 ± 0.085
End of Treatment (n=166, 190)-0.129 ± 0.290-0.144 ± 0.280
SecondaryNumber of Participants With Adverse Events (AEs) and the Number of Participants Who Died

The number of participants with serious AEs (SAEs), other non-serious AEs and participants who died. A summary of SAEs and other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.

Time frame:
Baseline to study completion (up to 37 months)
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs) and the Number of Participants Who Died
participantsRamucirumab (IMC-1121B) + BSCPlacebo + BSC
SAEs12392
Other Non-SAEs254235
Died215220
SecondaryMaximum Concentration (Cmax) of Ramucirumab, Cycle 1
Time frame:
1 hour following the completion of Cycle 1 (14-day cycle) infusion
Reported as:
Geometric mean · micrograms/milliliter (µg/mL)
Maximum Concentration (Cmax) of Ramucirumab, Cycle 1
micrograms/milliliter (µg/mL)Ramucirumab (IMC-1121B) + BSC
Maximum Concentration (Cmax) of Ramucirumab, Cycle 1149.6 ± 36.9
SecondaryCmax of Ramucirumab, Cycle 4
Time frame:
1 hour following completion of Cycle 4 (14-day cycles) infusion
Reported as:
Geometric mean · µg/mL
Cmax of Ramucirumab, Cycle 4
µg/mLRamucirumab (IMC-1121B) + BSC
Cmax of Ramucirumab, Cycle 4189.5 ± 39.1
SecondaryCmax of Ramucirumab, Cycle 7
Time frame:
1 hour following completion of Cycle 7 (14-day cycles) infusion
Reported as:
Geometric mean · µg/mL
Cmax of Ramucirumab, Cycle 7
µg/mLRamucirumab (IMC-1121B) + BSC
Cmax of Ramucirumab, Cycle 7184.4 ± 56.3
SecondaryNumber of Participants With Treatment Emergent Positive Anti-Ramucirumab Response [Serum Anti-Ramucirumab Antibody Assessment (Immunogenicity)]

Participants were considered positive for anti-ramucirumab antibodies \[anti-drug antibodies (ADA)\] if the post-treatment sample had an increase of at least 4-fold in titer from the pretreatment values. If the pretreatment value was not detected or was not present, a 1:20 post-treatment titer was required to indicate treatment emergence of ADA.

Time frame:
Prior to treatment and 1 hour post end of infusion for Cycles 1, 4 and 7 (14-day cycles)
Reported as:
Number · participants
Number of Participants With Treatment Emergent Positive Anti-Ramucirumab Response [Serum Anti-Ramucirumab Antibody Assessment (Immunogenicity)]
participantsRamucirumab (IMC-1121B) + BSCPlacebo + BSC
Number of Participants With Treatment Emergent Positive Anti-Ramucirumab Response [Serum Anti-Ramucirumab Antibody Assessment (Immunogenicity)]107

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ramucirumab (IMC-1121B) + BSC—124/277 (44.8%)254/277 (91.7%)
Placebo + BSC—92/276 (33.3%)235/276 (85.1%)
Most frequent serious events
Showing 10 of 158
Most frequent serious events
EventRamucirumab (IMC-1121B) + BSCPlacebo + BSC
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)23/27716/276
Hepatic encephalopathyNervous system disorders12/2771/276
Oesophageal varices haemorrhageGastrointestinal disorders4/27710/276
Abdominal painGastrointestinal disorders6/2779/276
General physical health deteriorationGeneral disorders9/2773/276
AscitesGastrointestinal disorders8/2773/276
Gastrointestinal haemorrhageGastrointestinal disorders7/2770/276
PyrexiaGeneral disorders7/2773/276
Hepatic failureHepatobiliary disorders6/2775/276
CholangitisHepatobiliary disorders5/2771/276
Most frequent other events
Showing 10 of 40
Most frequent other events
EventRamucirumab (IMC-1121B) + BSCPlacebo + BSC
Oedema peripheralGeneral disorders100/27750/276
AscitesGastrointestinal disorders72/27740/276
FatigueGeneral disorders66/27760/276
Decreased appetiteMetabolism and nutrition disorders59/27750/276
Abdominal painGastrointestinal disorders45/27758/276
HypertensionVascular disorders55/27720/276
HeadacheNervous system disorders53/27715/276
NauseaGastrointestinal disorders52/27752/276
DiarrhoeaGastrointestinal disorders50/27738/276
AstheniaGeneral disorders50/27736/276

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)Ramucirumab (IMC-1121B) + BSCPlacebo + BSCTotal
Mean62.9 ± 11.5662.5 ± 11.1062.7 ± 11.33
Age, Customized
Age, Customized(participants)Ramucirumab (IMC-1121B) + BSCPlacebo + BSCTotal
<65 years150162312
≥65 years133120253
Sex: Female, Male
Sex: Female, Male(Participants)Ramucirumab (IMC-1121B) + BSCPlacebo + BSCTotal
Female474087
Male236242478
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ramucirumab (IMC-1121B) + BSCPlacebo + BSCTotal
Hispanic or Latino232043
Not Hispanic or Latino253260513
Unknown or Not Reported729
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ramucirumab (IMC-1121B) + BSCPlacebo + BSCTotal
American Indian or Alaska Native000
Asian131135266
Native Hawaiian or Other Pacific Islander000
Black or African American538
White139137276
More than one race000
Unknown or Not Reported8715
Region of Enrollment
Region of Enrollment(participants)Ramucirumab (IMC-1121B) + BSCPlacebo + BSCTotal
United States172037
Portugal022
Philippines101
Taiwan332558
Hong Kong141024
Spain91221
Thailand516
Israel112
Switzerland112
Italy331851
France322759
Australia3811
Netherlands213
Korea, Republic of284270
Finland033
Austria448
Czech Republic11920
Hungary101
Canada011
Belgium358
Brazil151227
Romania347
Bulgaria246
Germany192140
Norway112
Japan454893
Sweden022
08

Study locations

146 sites
  • ImClone Investigational Site
    Orange, California 92868, United States
  • ImClone Investigational Site
    San Francisco, California 94115, United States
  • ImClone Investigational Site
    New Haven, Connecticut 06520, United States
  • ImClone Investigational Site
    Jacksonville, Florida 32207, United States
  • ImClone Investigational Site
    New Orleans, Louisiana 70112, United States
  • ImClone Investigational Site
    Boston, Massachusetts 02111, United States
  • ImClone Investigational Site
    Worcester, Massachusetts 01655, United States
  • ImClone Investigational Site
    Ann Arbor, Michigan 48109, United States
  • ImClone Investigational Site
    St Louis, Missouri 63110, United States
  • ImClone Investigational Site
    Newark, New Jersey 07103, United States
  • ImClone Investigational Site
    New York, New York 10029, United States
  • ImClone Investigational Site
    Winston-Salem, North Carolina 27157, United States
  • ImClone Investigational Site
    Dayton, Ohio 45420, United States
  • ImClone Investigational Site
    Philadelphia, Pennsylvania 19141, United States
  • ImClone Investigational Site
    Charleston, South Carolina 29414, United States
  • ImClone Investigational Site
    Lubbock, Texas 79415, United States
  • ImClone Investigational Site
    Seattle, Washington 98109, United States
  • ImClone Investigational Site
    Milwaukee, Wisconsin 53226, United States
  • ImClone Investigational Site
    Bankstown, New South Wales 2200, Australia
  • ImClone Investigational Site
    Kogarah, New South Wales 2217, Australia
  • ImClone Investigational Site
    Liverpool Bc, New South Wales 1871, Australia
  • ImClone Investigational Site
    Kurralta Park, South Australia 5037, Australia
  • ImClone Investigational Site
    Prahran, Victoria 3181, Australia
  • ImClone Investigational Site
    Linz, 4021, Austria
  • ImClone Investigational Site
    Salzburg, 5020, Austria
  • ImClone Investigational Site
    Steyr, 4400, Austria
  • ImClone Investigational Site
    Vienna, A1090, Austria
  • ImClone Investigational Site
    Bonheiden, 2820, Belgium
  • ImClone Investigational Site
    Brussels, 01200, Belgium
  • ImClone Investigational Site
    Charleroi, 6000, Belgium
  • ImClone Investigational Site
    Edegem, 2650, Belgium
  • ImClone Investigational Site
    Leuven, 03000, Belgium
  • ImClone Investigational Site
    Liège, 4000, Belgium
  • ImClone Investigational Site
    Ottignies, 1340, Belgium
  • ImClone Investigational Site
    Belo Horizonte, 30110090, Brazil
  • ImClone Investigational Site
    Botucatu, 18618-970, Brazil
  • ImClone Investigational Site
    Brasilia, 72115-700, Brazil
  • ImClone Investigational Site
    Campinas, 13083-970, Brazil
  • ImClone Investigational Site
    Ijui, 98700 000, Brazil
  • ImClone Investigational Site
    Ribeirao Preto, 14049-900, Brazil
  • ImClone Investigational Site
    Rio De Janeiro, 21941-31, Brazil
  • ImClone Investigational Site
    Salvador, 41825-010, Brazil
  • ImClone Investigational Site
    Sao Jose Rio Preto, 15090-000, Brazil
  • ImClone Investigational Site
    São Paulo, 04039-901, Brazil
  • ImClone Investigational Site
    Plovdiv, 4004, Bulgaria
  • ImClone Investigational Site
    Sofia, 1527, Bulgaria
  • ImClone Investigational Site
    Varna, 9010, Bulgaria
  • ImClone Investigational Site
    Ottawa, Ontario K1H 8L6, Canada
  • ImClone Investigational Site
    Brib, 656 53, Czech Republic
  • ImClone Investigational Site
    Hradec Kralove, 500 05, Czech Republic
  • ImClone Investigational Site
    Olomouc, 775 20, Czech Republic
  • ImClone Investigational Site
    Prague, 150 06, Czech Republic
  • ImClone Investigational Site
    Helsinki, 180, Finland
  • ImClone Investigational Site
    Amiens, 80054, France
  • ImClone Investigational Site
    Angers, 49933, France
  • ImClone Investigational Site
    Avignon, 84000, France
  • ImClone Investigational Site
    Besancon, 25020, France
  • ImClone Investigational Site
    Bordeaux, 33000, France
  • ImClone Investigational Site
    Clermont-Ferrand, 63003, France
  • ImClone Investigational Site
    La Roche Sur Yon, 85925, France
  • ImClone Investigational Site
    Limoges, 87042, France
  • ImClone Investigational Site
    Marseille, 13385, France
  • ImClone Investigational Site
    Nice, 06200, France
  • ImClone Investigational Site
    Paris, 75674, France
  • ImClone Investigational Site
    Poitiers, 86021, France
  • ImClone Investigational Site
    Reims, 51092, France
  • ImClone Investigational Site
    Saint-Etienne, 42055, France
  • ImClone Investigational Site
    Berlin, 12203, Germany
  • ImClone Investigational Site
    Bielefeld, 33611, Germany
  • ImClone Investigational Site
    Bonn, 53105, Germany
  • ImClone Investigational Site
    Düsseldorf, 40225, Germany
  • ImClone Investigational Site
    Essen, 45122, Germany
  • ImClone Investigational Site
    Frankfurt, 60596, Germany
  • ImClone Investigational Site
    Freiburg, 79106, Germany
  • ImClone Investigational Site
    Hamburg, 20246, Germany
  • ImClone Investigational Site
    Hannover, 30625, Germany
  • ImClone Investigational Site
    Homburg, 66421, Germany
  • ImClone Investigational Site
    Leipzig, 04103, Germany
  • ImClone Investigational Site
    Magdeburg, 39120, Germany
  • ImClone Investigational Site
    Munich, 81377, Germany
  • ImClone Investigational Site
    Münster, 48149, Germany
  • ImClone Investigational Site
    Tübingen, 72076, Germany
  • ImClone Investigational Site
    Ulm, 89081, Germany
  • ImClone Investigational Site
    Weiden, 92637, Germany
  • ImClone Investigational Site
    Kowloon, Hong Kong
  • ImClone Investigational Site
    Pokfulam, Hong Kong
  • ImClone Investigational Site
    Shatin, Hong Kong
  • ImClone Investigational Site
    Budapest, 1122, Hungary
  • ImClone Investigational Site
    Beer Sheva, 84101, Israel
  • ImClone Investigational Site
    Petah Tiqva, 49100, Israel
  • ImClone Investigational Site
    Tel Aviv, 64239, Israel
  • ImClone Investigational Site
    Bari, 70124, Italy
  • ImClone Investigational Site
    Benevento, 82100, Italy
  • ImClone Investigational Site
    Bologna, 40100, Italy
  • ImClone Investigational Site
    Genova, 16132, Italy
  • ImClone Investigational Site
    Lecce, 73100, Italy
  • ImClone Investigational Site
    Milano, 20122, Italy
  • ImClone Investigational Site
    Modena, 41100, Italy
  • ImClone Investigational Site
    Padova, 35128, Italy
  • ImClone Investigational Site
    Palermo, 90127, Italy

Showing the first 100 of 146 sites across 27 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Llovet JM, Singal AG, Villanueva A, Finn RS, Kudo M, Galle PR, Ikeda M, Callies S, McGrath LM, Wang C, Abada P, Widau RC, Gonzalez-Gugel E, Zhu AX. Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials. Clin Cancer Res. 2022 Jun 1;28(11):2297-2305. doi: 10.1158/1078-0432.CCR-21-4000. PubMed 35247922 ↗
  • Mitani S, Chen Y, Inoue K, Mori J, Gao L, Long A, Wakabayashi S. Clinical Impact of a Shortened Infusion Duration of Ramucirumab in Japanese Patients -A Model-Based Approach. Gan To Kagaku Ryoho. 2021 Nov;48(11):1381-1387. PubMed 34795131 ↗
  • Zhu AX, Finn RS, Kang YK, Yen CJ, Galle PR, Llovet JM, Assenat E, Brandi G, Motomura K, Ohno I, Daniele B, Vogel A, Yamashita T, Hsu CH, Gerken G, Bilbruck J, Hsu Y, Liang K, Widau RC, Wang C, Abada P, Kudo M. Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab. Br J Cancer. 2021 Apr;124(8):1388-1397. doi: 10.1038/s41416-021-01260-w. Epub 2021 Feb 3. PubMed 33531690 ↗
  • Reig M, Galle PR, Kudo M, Finn R, Llovet JM, Metti AL, Schelman WR, Liang K, Wang C, Widau RC, Abada P, Zhu AX. Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab. Liver Int. 2021 Mar;41(3):598-607. doi: 10.1111/liv.14731. Epub 2020 Dec 5. PubMed 33188713 ↗
  • Zhu AX, Nipp RD, Finn RS, Galle PR, Llovet JM, Blanc JF, Okusaka T, Chau I, Cella D, Girvan A, Gable J, Bowman L, Wang C, Hsu Y, Abada PB, Kudo M. Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials. ESMO Open. 2020 Aug;5(4):e000797. doi: 10.1136/esmoopen-2020-000797. PubMed 32817068 ↗
  • Kudo M, Okusaka T, Motomura K, Ohno I, Morimoto M, Seo S, Wada Y, Sato S, Yamashita T, Furukawa M, Aramaki T, Nadano S, Ohkawa K, Fujii H, Kudo T, Furuse J, Takai H, Homma G, Yoshikawa R, Zhu AX. Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial. J Gastroenterol. 2020 Jun;55(6):627-639. doi: 10.1007/s00535-020-01668-w. Epub 2020 Feb 27. PubMed 32107609 ↗
  • Arnold D, Fuchs CS, Tabernero J, Ohtsu A, Zhu AX, Garon EB, Mackey JR, Paz-Ares L, Baron AD, Okusaka T, Yoshino T, Yoon HH, Das M, Ferry D, Zhang Y, Lin Y, Binder P, Sashegyi A, Chau I. Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab. Ann Oncol. 2017 Dec 1;28(12):2932-2942. doi: 10.1093/annonc/mdx514. PubMed 28950290 ↗
  • Chau I, Peck-Radosavljevic M, Borg C, Malfertheiner P, Seitz JF, Park JO, Ryoo BY, Yen CJ, Kudo M, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Okusaka T, Bowman L, Cui ZL, Girvan AC, Abada PB, Yang L, Zhu AX. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study. Eur J Cancer. 2017 Aug;81:17-25. doi: 10.1016/j.ejca.2017.05.001. Epub 2017 Jun 4. Erratum In: Eur J Cancer. 2018 Sep;100:135-136. doi: 10.1016/j.ejca.2018.06.002. PubMed 28591675 ↗
  • Zhu AX, Baron AD, Malfertheiner P, Kudo M, Kawazoe S, Pezet D, Weissinger F, Brandi G, Barone CA, Okusaka T, Wada Y, Park JO, Ryoo BY, Cho JY, Chung HC, Li CP, Yen CJ, Lee KD, Chang SC, Yang L, Abada PB, Chau I. Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma: Analysis of REACH Trial Results by Child-Pugh Score. JAMA Oncol. 2017 Feb 1;3(2):235-243. doi: 10.1001/jamaoncol.2016.4115. PubMed 27657674 ↗
  • Kudo M, Hatano E, Ohkawa S, Fujii H, Masumoto A, Furuse J, Wada Y, Ishii H, Obi S, Kaneko S, Kawazoe S, Yokosuka O, Ikeda M, Ukai K, Morita S, Tsuji A, Kudo T, Shimada M, Osaki Y, Tateishi R, Sugiyama G, Abada PB, Yang L, Okusaka T, Zhu AX. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial. J Gastroenterol. 2017 Apr;52(4):494-503. doi: 10.1007/s00535-016-1247-4. Epub 2016 Aug 22. PubMed 27549242 ↗
  • Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Pfiffer TE, Okusaka T, Kubackova K, Trojan J, Sastre J, Chau I, Chang SC, Abada PB, Yang L, Schwartz JD, Kudo M; REACH Trial Investigators. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2015 Jul;16(7):859-70. doi: 10.1016/S1470-2045(15)00050-9. Epub 2015 Jun 18. PubMed 26095784 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2010, a primary completion of Mar 2014 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2015, 1 year after primary completion. A results delay was requested in Jul 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2010
First posted
Jun 9, 2010
Start
Oct 2010
Primary completionActual
Mar 2014
CompletionActual
Mar 2015
Results delay requested
Jul 29, 2010
Results first posted
Mar 26, 2015
Last update
Dec 28, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 28, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01140347
Responsible party
Sponsor
First posted
Jun 9, 2010
Start date
Oct 2010
Primary completion
Mar 2014
Completion
Mar 2015
Results posted
Mar 26, 2015
Last update
Dec 28, 2015

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ramucirumab

Start the discussion